# EDGAR Filing Document

**Accession Number:** 0001037868
**File Stem:** 0001037868-26-000144
**Filing Date:** 2026-4
**Character Count:** 94837
**Document Hash:** 6f79251f75ee14a6df32a0b5b5e91997
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001037868-26-000144.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001037868-26-000144

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 84

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMETEK INC/
- **CENTRAL INDEX KEY:** 0001037868
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 141682544
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12981
- **FILM NUMBER:** 26923498

**BUSINESS ADDRESS:**
- **STREET 1:** 1100 CASSATT ROAD
- **CITY:** BERWYN
- **STATE:** PA
- **ZIP:** 19312
- **BUSINESS PHONE:** 610-647-2121

**MAIL ADDRESS:**
- **STREET 1:** 1100 CASSATT ROAD
- **CITY:** BERWYN
- **STATE:** PA
- **ZIP:** 19312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMETEK AEROSPACE PRODUCTS INC
- **DATE OF NAME CHANGE:** 19970415

?xml version='1.0' encoding='ASCII'? ame-20260331

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**_________________________**

**FORM 10-Q** 

**_________________________**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026** 

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**

**Commission File Number 1-12981** 

**_________________________**

**AMETEK, Inc.** 

**(Exact name of registrant as specified in its charter)**

**_________________________**

**Delaware** 

**(State or other jurisdiction of**

**incorporation or organization)**

**1100 Cassatt Road** 

**Berwyn, Pennsylvania** 

**(Address of principal executive offices)**

**14-1682544** 

**(I.R.S. Employer**

**Identification No.)**

**19312-1177** 

**(Zip Code)**

**Registrant's telephone number, including area code: (610) 647-2121** 

**_________________________**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐  | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

**_________________________**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Common Stock** | **AME** | **New York Stock Exchange** |

---

The number of shares of the registrant's common stock outstanding as of the latest practicable date was: Common Stock, $0.01 Par Value, outstanding at April 24, 2026 was 229,203,002 shares.

------

**AMETEK, Inc.**

**Form 10-Q**

**Table of Contents**

---

| | |
|:---|:---|
| | **Page** |
| **<u>[PART I. FINANCIAL INFORMATION](#ib9dd6fad079d4766b2733344dd3cbc40_10)</u>** | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1.Financial Statements](#ib9dd6fad079d4766b2733344dd3cbc40_13)</u> |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statement of Income for the three months ended March 31, 2026 and 2025](#ib9dd6fad079d4766b2733344dd3cbc40_16)</u> | [3](#ib9dd6fad079d4766b2733344dd3cbc40_16) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statement of Comprehensive Income for the three months ended March 31, 2026 and 2025](#ib9dd6fad079d4766b2733344dd3cbc40_19)</u> | [4](#ib9dd6fad079d4766b2733344dd3cbc40_1071) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheet at March 31, 2026 and December 31, 2025](#ib9dd6fad079d4766b2733344dd3cbc40_22)</u> | [5](#ib9dd6fad079d4766b2733344dd3cbc40_22) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statement of Stockholders' Equity for the three months ended March 31, 2026 and 2025](#ib9dd6fad079d4766b2733344dd3cbc40_25)</u> | [6](#ib9dd6fad079d4766b2733344dd3cbc40_1058) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Condensed Consolidated Statement of Cash Flows for the three months ended March 31, 2026 and 2025](#ib9dd6fad079d4766b2733344dd3cbc40_28)</u> | [7](#ib9dd6fad079d4766b2733344dd3cbc40_28) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to Consolidated Financial Statements](#ib9dd6fad079d4766b2733344dd3cbc40_31)</u> | [8](#ib9dd6fad079d4766b2733344dd3cbc40_31) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations](#ib9dd6fad079d4766b2733344dd3cbc40_94)</u> | [22](#ib9dd6fad079d4766b2733344dd3cbc40_94) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4.Controls and Procedures](#ib9dd6fad079d4766b2733344dd3cbc40_112)</u> | [25](#ib9dd6fad079d4766b2733344dd3cbc40_112) |
| **<u>[PART II. OTHER INFORMATION](#ib9dd6fad079d4766b2733344dd3cbc40_115)</u>** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2.Unregistered Sales of Equity Securities and Use of Proceeds](#ib9dd6fad079d4766b2733344dd3cbc40_121)</u> | [26](#ib9dd6fad079d4766b2733344dd3cbc40_121) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>[Item 5. Other Information](#ib9dd6fad079d4766b2733344dd3cbc40_124)</u> | [26](#ib9dd6fad079d4766b2733344dd3cbc40_121) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 6.Exhibits](#ib9dd6fad079d4766b2733344dd3cbc40_127)</u> | [27](#ib9dd6fad079d4766b2733344dd3cbc40_127) |
| **<u>[SIGNATURES](#ib9dd6fad079d4766b2733344dd3cbc40_130)</u>** | [28](#ib9dd6fad079d4766b2733344dd3cbc40_130) |

---

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**AMETEK, Inc.**

**Consolidated Statement of Income**

**(In thousands, except per share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Net sales** | $**1928437** | $1731971 |
| Cost of sales | **1210878** | 1106971 |
| Selling, general and administrative | **202623** | 170171 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | **1413501** | 1277142 |
| **Operating income** | **514936** | 454829 |
| Interest expense | **(20909)** | (18993) |
| Other (expense) income, net | **(1047)** | (1614) |
| **Income before income taxes** | **492980** | 434222 |
| Provision for income taxes | **93623** | 82464 |
| **Net income** | $**399357** | $351758 |
| Basic earnings per share | $**1.74** | $1.52 |
| **Diluted earnings per share** | $**1.74** | $1.52 |
| Weighted average common shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic shares | **228903** | 230668 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted shares | **229835** | 231542 |
| Dividends declared and paid per share | $**0.34** | $0.31 |

---

See accompanying notes.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Consolidated Statement of Comprehensive Income** 

**(In thousands)** 

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Net income** | $**399357** | $351758 |
| **Other comprehensive income (loss):** |  |  |
| Amounts arising during the period – gains (losses), net of tax (expense) benefit: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Translation adjustments | **(49329)** | 65778 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in long-term intercompany notes | **1511** | (3116) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net investment hedge instruments gain (loss), net of tax of $(4397) and $8,099 for the quarter ended March 31, 2026 and 2025, respectively | **14010** | (25801) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defined benefit pension plans: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of net actuarial loss, net of tax of $(167) and $(296) for the quarter ended March 31, 2026 and 2025, respectively | **531** | 942 |
| **Other comprehensive (loss) income** | **(33277)** | 37803 |
| **Total comprehensive income** | $**366080** | $389561 |

---

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Consolidated Balance Sheet**

**(In thousands)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| | **(Unaudited)** | |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**481250** | $457951 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | **1153951** | 1119257 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **1143418** | 1106405 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **358889** | 336229 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **3137508** | 3019842 |
| Property, plant and equipment, net | **840388** | 855215 |
| Right of use assets, net | **263167** | 273142 |
| Goodwill | **7266351** | 7170770 |
| Other intangibles, net | **4165088** | 4128394 |
| Investments and other assets | **637033** | 620180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $**16309535** | $16067543 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term borrowings and current portion of long-term debt, net | $**1114946** | $1208975 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **619255** | 617950 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer advanced payments | **463706** | 396177 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | **91169** | 82682 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities and other | **467060** | 536968 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **2756136** | 2842752 |
| Long-term debt, net | **1062603** | 1074334 |
| Deferred income taxes | **839748** | 788915 |
| Other long-term liabilities | **731751** | 732756 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | **5390238** | 5438757 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.01 par value | **2728** | 2725 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital in excess of par value | **1314400** | 1317288 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **12574041** | 12252480 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(432497)** | (399220) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock | **(2539375)** | (2544487) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | **10919297** | 10628786 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $**16309535** | $16067543 |

---

See accompanying notes.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Consolidated Statement of Stockholders' Equity**

**(In thousands)**

**(Unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common stock** | **Capital in excess of par value** | **Retained earnings** | **Accumulated other comprehensive (loss) income** | **Treasury stock** | **Total stockholders' equity** |
| <u>Three months ended March 31, 2026</u> |  |  |  |  |  |  |
| Balance at December 31, 2025 | $**2725** | $**1317288** | $**12252480** | $**(399220)** | $**(2544487)** | $**10628786** |
| &nbsp;&nbsp;Net income | **—** | **—** | **399357** | **—** | **—** | **399357** |
| &nbsp;&nbsp;Shares issued | **3** | **—** | **—** | **—** | **—** | **3** |
| &nbsp;&nbsp;Issuance of common stock under employee stock plans | **—** | **(12596)** | **—** | **—** | **13046** | **450** |
| &nbsp;&nbsp;Share-based compensation expense | **—** | **9708** | **—** | **—** | **—** | **9708** |
| &nbsp;&nbsp;Cash dividends paid | **—** | **—** | **(77796)** | **—** | **—** | **(77796)** |
| &nbsp;&nbsp;Other comprehensive (loss) income | **—** | **—** | **—** | **(33277)** | **—** | **(33277)** |
| &nbsp;&nbsp;Purchase of treasury stock | **—** | **—** | **—** | **—** | **(7934)** | **(7934)** |
| &nbsp;&nbsp;Other | **—** | **—** | **—** | **—** | **—** | **—** |
| Balance at March 31, 2026 | $**2728** | $**1314400** | $**12574041** | $**(432497)** | $**(2539375)** | $**10919297** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| <u>Three months ended March 31, 2025</u> |  |  |  |  |  |  |
| Balance at December 31, 2024 | $2720 | $1264670 | $11057684 | $(555739) | $(2114031) | $9655304 |
| &nbsp;&nbsp;Net income |  |  | 351758 |  |  | 351758 |
| &nbsp;&nbsp;Shares issued | 2 |  |  |  |  | 2 |
| &nbsp;&nbsp;Issuance of common stock under employee stock plans |  | (19116) |  |  | 13152 | (5964) |
| &nbsp;&nbsp;Share-based compensation expense |  | 9464 |  |  |  | 9464 |
| &nbsp;&nbsp;Cash dividends paid |  |  | (71455) |  |  | (71455) |
| &nbsp;&nbsp;Other comprehensive (loss) income |  |  |  | 37803 |  | 37803 |
| &nbsp;&nbsp;Purchase of treasury stock |  |  |  |  | (6966) | (6966) |
| &nbsp;&nbsp;Other |  |  |  |  |  |  |
| Balance at March 31, 2025 | $2722 | $1255018 | $11337987 | $(517936) | $(2107845) | $9969946 |

---

See accompanying notes.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Condensed Consolidated Statement of Cash Flows**

**(In thousands)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three months ended March 31,** | **Three months ended March 31,** |
| | **2026** | **2025** |
| **Cash provided by (used for):** |  |  |
| **Operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $**399357** | $351758 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to total operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **105490** | 106367 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **16062** | (1328) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | **9708** | 9464 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in assets and liabilities, net of acquisitions | **(51985)** | (42196) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension contributions | **(1412)** | (1462) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | **(25704)** | (5058) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating activities | **451516** | 417545 |
| **Investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions to property, plant and equipment | **(25468)** | (23069) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of businesses, net of cash acquired | **(209558)** | (103165) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | **473** | 521 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total investing activities | **(234553)** | (125713) |
| **Financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change in short-term borrowings | **(82689)** | (185093) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repurchases of common stock | **(27935)** | (18011) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash dividends paid | **(77796)** | (71455) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from stock option exercises | **9643** | 4669 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | **(9187)** | (7803) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total financing activities | **(187964)** | (277693) |
| Effect of exchange rate changes on cash and cash equivalents | **(5700)** | 10863 |
| Increase (decrease) in cash and cash equivalents | **23299** | 25002 |
| Cash and cash equivalents: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beginning of period | 457951 | 373999 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End of period | $**481250** | $399001 |

---

See accompanying notes.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**1.&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation**

The accompanying consolidated financial statements are unaudited. AMETEK, Inc. (the "Company") believes that all adjustments (which primarily consist of normal recurring accruals) necessary for a fair presentation of the consolidated financial position of the Company at March 31, 2026, the consolidated results of its operations for the three months ended March 31, 2026 and 2025 and its cash flows for the three months ended March 31, 2026 and 2025 have been included. The Company has two reportable segments, Electronic Instruments Group ("EIG") and Electromechanical Group ("EMG"). The Company identifies its operating segments for segment reporting purposes primarily on the basis of product type, production processes, distribution methods and management organizations. Quarterly results of operations are not necessarily indicative of results for the full year. The accompanying consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the U.S. Securities and Exchange Commission.

**2.&nbsp;&nbsp;&nbsp;&nbsp;Recent Accounting Pronouncements**

*Recent Accounting Pronouncements*

In November 2025, the FASB issued ASU 2025-09, Derivatives and Hedging (Topic 815) - Hedge Accounting Improvements ("ASU 2025-09"). The amendments in this update aim to better align financial reporting with an entity's risk management strategies. It makes improvements in five key areas to help entities achieve and maintain hedge accounting for highly effective economic hedges. Improvements include changes to similar risk assessment for cash flow hedges, a new model for Choose-Your-Rate debt instruments, a principles-based approach for nonfinancial forecasted transactions, clarification on net written options, and addressing the mismatch in dual-hedge accounting. ASU 2025-09 is effective for annual periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. The Company is evaluating the impact ASU 2025-09 may have on the Company's financial statement disclosures.

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06) updating guidance on accounting for internal-use software. The amendments modernize guidance to consider different methods of software development, updating the requirements for capitalization of software costs. ASU 2025-06 is effective for annual and interim reporting periods beginning after December 15, 2027. Prospective, modified prospective, or retrospective application is allowed and early adoption is permitted. The Company has not determined the impact ASU 2025-06 may have on the Company's consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income —Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosures about significant expenses included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Prospective or retrospective application is allowed and early adoption is permitted. The Company has not determined the impact ASU 2024-03 may have on the Company's financial statement disclosures.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**3.&nbsp;&nbsp;&nbsp;&nbsp;Revenues**

The outstanding contract asset and liability accounts were as follows:

---

| | | |
|:---|:---|:---|
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| Contract assets—January 1 | $159896 | $136432 |
| Contract assets – March 31 | **178306** | 157815 |
| Change in contract assets – increase (decrease) | **18410** | 21383 |
| Contract liabilities – January 1 | 448849 | 400689 |
| Contract liabilities – March 31 | **505507** | 426235 |
| Change in contract liabilities – (increase) decrease | **(56658)** | (25546) |
| Net change | $**(38248)** | $(4163) |

---

The net change for the three months ended March 31, 2026 was primarily driven by an increase in customer advance payments. For the three months ended March 31, 2026 and 2025, the Company recognized revenue of $261.5 million and $182.5 million, respectively, that was previously included in the beginning balance of contract liabilities.

Contract assets are reported as a component of Other current assets in the consolidated balance sheet. At March 31, 2026 and December 31, 2025, $41.8 million and $52.7 million of Customer advanced payments (contract liabilities), respectively, were recorded in Other long-term liabilities in the consolidated balance sheets.

The remaining performance obligations not expected to be completed within one year as of March 31, 2026 and December 31, 2025 were $684.7 million and $627.4 million, respectively. Remaining performance obligations represent the transaction price of firm, non-cancelable orders, with expected delivery dates to customers greater than one year from the balance sheet date, for which the performance obligation is unsatisfied or partially unsatisfied. These performance obligations will be substantially satisfied within two to three years.

*Geographic Areas*

Net sales were attributed to geographic areas based on the location of the customer. Information about the Company's operations in different geographic areas was as follows for the three months ended March 31:

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| United States | $**619384** | $**385391** | $**1004775** |
| International<sup>(1)</sup>: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United Kingdom | **34177** | **38060** | **72237** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;European Union countries | **162015** | **128577** | **290592** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia | **323467** | **66567** | **390034** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other foreign countries | **125493** | **45306** | **170799** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total international | **645152** | **278510** | **923662** |
| Consolidated net sales | $**1264536** | $**663901** | $**1928437** |

---

________________

(1)&nbsp;&nbsp;&nbsp;&nbsp;Includes U.S. export sales of $533.4 million for the three months ended March 31, 2026.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| United States | $580125 | $347405 | $927530 |
| International<sup>(1)</sup>: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United Kingdom | 30817 | 37806 | 68623 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;European Union countries | 132466 | 104185 | 236651 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asia | 274865 | 55178 | 330043 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other foreign countries | 125400 | 43724 | 169124 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total international | 563548 | 240893 | 804441 |
| Consolidated net sales | $1143673 | $588298 | $1731971 |

---

______________

(1)&nbsp;&nbsp;&nbsp;&nbsp;Includes U.S. export sales of $470.0 million for the three months ended March 31, 2025.

*Major Products and Services*

The Company's major products and services in the reportable segments were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Process and analytical instrumentation | $**891630** | $**—** | $**891630** |
| Aerospace and power | **372906** | **196595** | **569501** |
| Automation and engineered solutions | **—** | **467306** | **467306** |
| Consolidated net sales | $**1264536** | $**663901** | $**1928437** |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Process and analytical instrumentation | $776871 | $— | $776871 |
| Aerospace and power | 366802 | 171908 | 538710 |
| Automation and engineered solutions |  | 416390 | 416390 |
| Consolidated net sales | $1143673 | $588298 | $1731971 |

---

*Timing of Revenue Recognition*

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** | **Three months ended March 31, 2026** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Products transferred at a point in time | $**1001212** | $**589065** | $**1590277** |
| Products and services transferred over time | **263324** | **74836** | **338160** |
| Consolidated net sales | $**1264536** | $**663901** | $**1928437** |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** | **Three months ended March 31, 2025** |
| | **EIG** | **EMG** | **Total** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Products transferred at a point in time | $906887 | $533408 | $1440295 |
| Products and services transferred over time | 236786 | 54890 | 291676 |
| Consolidated net sales | $1143673 | $588298 | $1731971 |

---

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

*Product Warranties*

The Company provides limited warranties in connection with the sale of its products. The warranty periods for products sold vary among the Company's operations, but the majority do not exceed one year. The Company calculates its warranty expense provision based on its historical warranty experience and adjustments are made periodically to reflect actual warranty expenses. Product warranty obligations are reported as a component of Accrued liabilities and other in the consolidated balance sheet.

Changes in the accrued product warranty obligation were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| Balance at the beginning of the period | $44738 | $38555 |
| Accruals for warranties issued during the period | **3809** | 5167 |
| Settlements made during the period | **(4931)** | (4846) |
| Warranty accruals related to acquired businesses and other during the period | **(201)** | 1345 |
| Balance at the end of the period | $**43415** | $40221 |

---

*Accounts Receivable*

The Company maintains allowances for estimated losses resulting from the inability of customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses, on all accounts receivable and contract assets, which considers risk of future credit losses based on factors such as historical experience, contract terms, as well as general and market business conditions, country, and political risk. Balances are written off when determined to be uncollectible.

At March 31, 2026, the Company had $1,154.0 million of accounts receivable, net of allowances of $13.5 million. At December 31, 2025, the Company had $1,119.3 million of accounts receivable, net of allowance of $13.7 million. Changes in the allowance were not material for the three months ended March 31, 2026.

**4.&nbsp;&nbsp;&nbsp;&nbsp;Earnings Per Share**

The calculation of basic earnings per share is based on the weighted average number of common shares considered outstanding during the periods. The calculation of diluted earnings per share reflects the effect of all potentially dilutive securities (principally outstanding stock options and restricted stock grants). The number of weighted average shares used in the calculation of basic earnings per share and diluted earnings per share was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| **Weighted average shares:** |  |  |
| Basic shares | **228903** | 230668 |
| Equity-based compensation plans | **932** | 874 |
| Diluted shares | **229835** | 231542 |

---

The calculation of diluted earnings per share for the three months ended March 31, 2025 excluded an immaterial number of stock options because the exercise prices of these stock options exceeded the average market price of the Company's common shares, and the effect of their inclusion would have been antidilutive. There were no antidilutive shares for the three months ended March 31, 2026.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**5.&nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurements**

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The Company utilizes a valuation hierarchy for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company's own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The following table provides the Company's assets that are measured at fair value on a recurring basis, consistent with the fair value hierarchy, at March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Mutual fund investments | $**8244** | $**8244** | $— | $— |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Total** | **Level 1** | **Level 2** | **Level 3** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Mutual fund investments | $8199 | $8199 | $— | $— |

---

The fair value of mutual fund investments is based on quoted market prices. The mutual fund investments are shown as a component of investments and other assets on the consolidated balance sheet.

For the three months ended March 31, 2026 and 2025, gains and losses on the investments noted above were not significant. No transfers between level 1 and level 2 investments occurred during the three months ended March 31, 2026 and 2025.

*Financial Instruments*

Cash, cash equivalents and mutual fund investments are recorded at fair value at March 31, 2026 and December 31, 2025 in the accompanying consolidated balance sheet.

The following table provides the estimated fair values of the Company's financial instrument liabilities, for which fair value is measured for disclosure purposes only, compared to the recorded amounts at March 31, 2026 and December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** |
| | **Recorded**<br>**Amount** | **Fair Value** | **Recorded**<br>**Amount** | **Fair Value** |
| | **(In thousands)** | **(In thousands)** | **(In thousands)** | **(In thousands)** |
| Long-term debt (including current portion) | $**(1508804)** | $**(1463418)** | $(1527238) | $(1488009) |

---

The fair value of net short-term borrowings approximates the carrying value. The Company's net long-term debt is all privately held with no public market for this debt, therefore, the fair value of net long-term debt was computed based on comparable current market data for similar debt instruments and is considered a level 3 liability.

**6.&nbsp;&nbsp;&nbsp;&nbsp;Hedging Activities**

The Company has designated certain foreign-currency-denominated long-term borrowings as hedges of the net investment in certain foreign operations. As of March 31, 2026, these net investment hedges included British-pound-and Euro-denominated long-term debt. These borrowings were designed to create net investment hedges in certain designated foreign

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

subsidiaries. The Company designated the British-pound- and Euro-denominated loans as hedging instruments to offset translation gains or losses on the net investment due to changes in the British pound and Euro exchange rates. These net investment hedges are evidenced by management's contemporaneous documentation supporting the hedge designation. Any gain or loss on the hedging instruments (the debt) following hedge designation is reported in accumulated other comprehensive income in the same manner as the translation adjustment on the hedged investment based on changes in the spot rate, which is used to measure hedge effectiveness.

At March 31, 2026, the Company had $296.6 million of British-pound-denominated loans and $662.2 million in Euro-denominated loans, which were designated as a hedge against the net investment in British pound and Euro functional currency foreign subsidiaries. As a result of the British-pound- and Euro-denominated loans designated and 100% effective as net investment hedges, $18.4 million of pre-tax currency remeasurement gains have been included in the foreign currency translation component of other comprehensive income for the three months ended March 31, 2026.

**7.&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| | **(In thousands)** | **(In thousands)** |
| Finished goods and parts | $**129367** | $112300 |
| Work in process | **191667** | 179792 |
| Raw materials and purchased parts | **822384** | 814313 |
| Total inventories, net | $**1143418** | $1106405 |

---

**8.&nbsp;&nbsp;&nbsp;&nbsp;Leases and Other Commitments**

The Company has commitments under operating leases for certain facilities, vehicles and equipment used in its operations. Cash used in operations for operating leases was not materially different from operating lease expense for the three months ended March 31, 2026 and 2025. The Company's leases have a weighted average remaining lease term of approximately seven years.

The components of lease expense were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| Operating lease cost | $**21200** | $20275 |
| Variable lease cost | **3696** | 3345 |
| Total lease cost | $**24896** | $23620 |

---

Supplemental balance sheet information related to leases was as follows:

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| | **(In thousands)** | **(In thousands)** |
| Right of use assets, net | $**263167** | $273142 |
| Lease liabilities included in Accrued Liabilities and other | **61031** | 61133 |
| Lease liabilities included in Other long-term liabilities | **217054** | 227066 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities | $**278085** | $288199 |

---

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

Maturities of lease liabilities as of March 31, 2026 were as follows:

---

| | |
|:---|:---|
| **Lease Liability Maturity Analysis** | **Operating Leases** |
| | **(In thousands)** |
| Remaining 2026 | $**54080** |
| **2027** | **62473** |
| **2028** | **50002** |
| **2029** | **41905** |
| **2030** | **34662** |
| Thereafter | **84759** |
| Total lease payments | **327881** |
| Less: imputed interest | **49796** |
|  | $**278085** |

---

The Company does not have any significant leases that have not yet commenced.

*Other Commitments*

In the ordinary course of its business, the Company issues guarantees, stand-by letters of credit and surety bonds to provide financial or performance assurance to third parties on behalf of its consolidated subsidiaries to support or enhance the subsidiary's stand-alone creditworthiness. At March 31, 2026, the maximum amount of future payment obligations relative to these various guarantees was $337.7 million and the outstanding liability under certain of those guarantees was $210.8 million.

**9.&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions**

The Company spent $209.6 million in cash, net of cash acquired, to acquire LKC Technologies ("LKC") in January 2026. LKC is a leading provider of innovative technologies to enable the effective diagnosis and management of ophthalmic conditions. LKC is part of EIG.

The following table represents the allocation of the purchase price for the net assets of the LKC acquisition based on the estimated fair values at acquisition (in millions):

---

| | |
|:---|:---|
| Property, plant and equipment | $**0.5** |
| Goodwill | **117.3** |
| Other intangible assets | **115.5** |
| Deferred income taxes | **(25.7)** |
| Net working capital and other<sup>(1)</sup> | **10.2** |
| Total purchase price | $**217.8** |
| Less: Acquisition date fair value of cash acquired | **(8.2)** |
| Total cash paid | $**209.6** |

---

________________

(1)Includes $1.3 million in accounts receivable, whose fair value, contractual cash flows and expected cash flows are approximately equal.

The amount allocated to goodwill is reflective of the benefits the Company expects to realize from the acquisitions. LKC's design and engineering capabilities complement the Company's existing ultra precision technologies business.

At March 31, 2026, the purchase price allocated to other intangible assets of $115.5 million consists of $21.0 million of indefinite-lived intangible trade names, which are not subject to amortization. The remaining $94.5 million of other intangible assets consists of $73.5 million of customer relationships, which are being amortized over a period of 15 years, and $21.0 million of purchased technology, which is being amortized over a period of 15 years. Amortization expense for each of the next five years for the 2026 acquisition is expected to approximate $6 million per year.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

The LKC acquisition had an immaterial impact on reported net sales, net income, and diluted earnings per share for the three months ended March 31, 2026. Had the acquisition been made at the beginning of 2026 or 2025, pro forma net sales, net income, and diluted earnings per share for the three months ended March 31, 2026 and 2025, would not have been materially different than the amounts reported.

The Company is in the process of finalizing the measurement of certain tangible assets and liabilities, including accounts receivable and inventory, as well as the associated income tax considerations, for its July 2025 acquisition of FARO Technologies. The Company is in the process of finalizing the measurement of the intangible assets and tangible assets and liabilities, as well as the associated income tax considerations, for its January 2026 acquisition of LKC.

In January 2025, the Company acquired Kern Microtechnik ("Kern"). The Kern acquisition included an $8.9 million estimated fair value contingent payment due upon Kern achieving certain cumulative revenue and EBITDA targets over the period January 1, 2025 to January 1, 2027. The contingent liability was based on a probabilistic approach using level 3 inputs. At March 31, 2026, there was no change to the estimated fair value of the contingent payment liability.

*Acquisition subsequent to March 31, 2026*

In April 2026, the Company entered into a definitive agreement to acquire First Aviation Services, Inc. ("First Aviation"), a leading provider of highly engineered, mission-critical defense and aviation maintenance, repair and overhaul services and a manufacturer of related proprietary components. First Aviation has annual sales of approximately $80 million. First Aviation will join the Electromechanical Group.

**10.&nbsp;&nbsp;&nbsp;&nbsp;Goodwill**

The changes in the carrying amounts of goodwill by segment were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **EIG** | **EMG** | **Total** |
| | **(In millions)** | **(In millions)** | **(In millions)** |
| Balance at December 31, 2025 | $5008.2 | $2162.6 | $7170.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill acquired from 2026 acquisitions | **117.3** | **—** | **117.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase price allocation adjustments and other | **(0.1)** | **—** | **(0.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustments | **(15.0)** | **(6.6)** | **(21.6)** |
| Balance at March 31, 2026 | $**5110.4** | $**2156.0** | $**7266.4** |

---

**11.&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes**

The effective tax rate for the three months ended March 31, 2026 and 2025 was 19.0%.

At March 31, 2026, the Company had gross uncertain tax benefits of $239.5 million, of which $190.8 million, if recognized, would impact the effective tax rate.

The following is a reconciliation of the liability for uncertain tax positions (in millions):

---

| | |
|:---|:---|
| Balance at December 31, 2025 | $229.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additions for tax positions | **10.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reductions for tax positions | **—** |
| Balance at March 31, 2026 | $**239.5** |

---

The additions above primarily reflect the tax positions for foreign tax planning initiatives. The Company recognizes interest and penalties accrued related to uncertain tax positions in income tax expense. The amounts recognized in income tax expense for interest and penalties during the three months ended March 31, 2026 and 2025 were not significant.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

The Organization for Economic Cooperation and Development's ("OECD") Pillar Two initiative set a 15% global minimum tax for certain multinationals, effective January 1, 2024, in most countries where the Company operates. In January 2026, new OECD guidance proposed a Side-by-Side ("SbS") framework to limit Pillar Two taxes for U.S.-parented groups. Relief is contingent upon the implementation of the SbS framework within each respective jurisdiction's domestic legislation. For the three months ended March 31, 2026, the Company has recorded any incremental top-up tax in its income tax expense, based on the currently enacted Pillar Two framework, in jurisdictions where the effective tax rate does not meet the 15% minimum threshold.

**12.&nbsp;&nbsp;&nbsp;&nbsp;Share-Based Compensation**

The Company's share-based compensation plans are described in Note 11, Share-Based Compensation, to the consolidated financial statements in Part II, Item 8, filed on the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

*Share Based Compensation Expense* 

Total share-based compensation expense was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| Stock option expense | $**2822** | $3263 |
| Restricted stock expense | **5262** | 5055 |
| Performance restricted stock unit expense | **1624** | 1146 |
| Total pre-tax expense | $**9708** | $9464 |

---

Pre-tax share-based compensation expense is included in the consolidated statement of income in either Cost of sales or Selling, general and administrative expenses, depending on where the recipient's cash compensation is reported.

*Stock Options* 

The fair value of each stock option grant is estimated on the grant date using a Black-Scholes-Merton option pricing model. The following weighted average assumptions were used in the Black-Scholes-Merton model to estimate the fair values of stock options granted during the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31, 2026** | **Year Ended December 31, 2025** |
| Expected volatility | **20.1%** | 22.7% |
| Expected term (years) | **5.0** | 5.0 |
| Risk-free interest rate | **3.87%** | 4.07% |
| Expected dividend yield | **0.64%** | 0.70% |
| Black-Scholes-Merton fair value per stock option granted | $**51.29** | $46.21 |

---

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

The following is a summary of the Company's stock option activity and related information:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Shares** | **Weighted<br>Average<br>Exercise<br>Price** | **Weighted<br>Average<br>Remaining<br>Contractual<br>Life** | **Aggregate<br>Intrinsic<br>Value** |
| | **(In thousands)** | | **(Years)** | **(In millions)** |
| Outstanding at December 31, 2025 | 1950 | $126.07 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | **234** | **212.77** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised | **(83)** | **111.40** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | **(10)** | **174.86** |  |  |
| Outstanding at March 31, 2026 | **2091** | $**136.12** | **6.3** | $**163.6** |
| Exercisable at March 31, 2026 | **1629** | $**119.29** | **5.4** | $**154.9** |

---

The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2026 was $9.1 million. The total fair value of stock options vested during the three months ended March 31, 2026 was $11.7 million. As of March 31, 2026, there was approximately $21.9 million of expected future pre-tax compensation expense related to the 0.5 million non-vested stock options outstanding, which is expected to be recognized over a weighted average period of approximately two years.

*Restricted Stock* 

The following is a summary of the Company's non-vested restricted stock activity and related information:

---

| | | |
|:---|:---|:---|
| | **Shares** | **Weighted<br>Average<br> Grant Date<br>Fair Value** |
| | **(In thousands)** | |
| Non-vested restricted stock outstanding at December 31, 2025 | 280 | $173.25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | **138** | **213.45** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | **(122)** | **167.48** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | **(9)** | **176.96** |
| Non-vested restricted stock outstanding at March 31, 2026 | **287** | $**194.98** |

---

The total fair value of restricted stock vested during the three months ended March 31, 2026 was $20.5 million. As of March 31, 2026, there was approximately $51.1 million of expected future pre-tax compensation expense related to the 0.3 million non-vested restricted shares outstanding, which is expected to be recognized over a weighted average period of approximately two years.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

*Performance Restricted Stock Units*

The following is a summary of the Company's non-vested performance restricted stock activity and related information:

---

| | | |
|:---|:---|:---|
| | **Shares** | **Weighted<br>Average<br> Grant Date<br>Fair Value** |
| | **(In thousands)** | |
| Non-vested performance restricted stock outstanding at December 31, 2025 | 240 | $166.06 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted | **79** | **212.77** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance assumption change <sup>1</sup> | **2** | **138.46** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vested | **(77)** | **138.46** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited | **(1)** | **163.73** |
| Non-vested performance restricted stock outstanding at March 31, 2026 | **243** | $**189.78** |

---

_________________________________________

<sup>1</sup> Reflects the number of PRSUs above target levels based on performance metrics.

As of March 31, 2026, there was approximately $23.3 million of expected future pre-tax compensation expense related to the 0.2 million non-vested restricted shares outstanding, which is expected to be recognized over a weighted average period of approximately one year.

**13.&nbsp;&nbsp;&nbsp;&nbsp;Retirement and Pension Plans**

The components of net periodic pension benefit expense (income) were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| | **(In thousands)** | **(In thousands)** |
| **Defined benefit plans:** |  |  |
| Service cost | $**506** | $572 |
| Interest cost | **7132** | 7175 |
| Expected return on plan assets | **(14453)** | (13094) |
| Amortization of net actuarial loss and other | **1472** | 2019 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension income | **(5343)** | (3328) |
| **Other plans:** |  |  |
| Defined contribution plans | **13479** | 12504 |
| Foreign plans and other | **1744** | 1804 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other plans | **15223** | 14308 |
| Total net pension expense | $**9880** | $10980 |

---

For defined benefit plans, the net periodic benefit income, other than the service cost component, is included in "Other (expense) income, net" in the consolidated statement of income.

For the three months ended March 31, 2026 and 2025, contributions to the Company's defined benefit pension plans were $1.4 million and $1.5 million, respectively. The Company's current estimate of 2026 contributions to its worldwide defined benefit pension plans is in line with the range disclosed in Note 12 of the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**14.&nbsp;&nbsp;&nbsp;&nbsp;Contingencies**

*Asbestos Litigation*

The Company (including its subsidiaries) has been named as a defendant in a number of asbestos-related lawsuits. Certain of these lawsuits relate to a business which was acquired by the Company and do not involve products which were manufactured or sold by the Company. In connection with these lawsuits, the seller of such business has agreed to indemnify the Company against these claims (the "Indemnified Claims"). The Indemnified Claims have been tendered to, and are being defended by, such seller. The seller has met its obligations, in all respects, and the Company does not have any reason to believe such party would fail to fulfill its obligations in the future. To date, no judgments have been rendered against the Company as a result of any asbestos-related lawsuit. The Company believes that it has good and valid defenses to each of these claims and intends to defend them vigorously.

*Environmental Matters*

Certain historic processes in the manufacture of products have resulted in environmentally hazardous waste by-products as defined by federal and state laws and regulations. At March 31, 2026, the Company is named a Potentially Responsible Party ("PRP") at 13 non-AMETEK-owned former waste disposal or treatment sites (the "non-owned" sites). The Company is identified as a "de minimis" party in a majority of these sites based on the low volume of waste attributed to the Company relative to the amounts attributed to other named PRPs. The Company is participating in the investigation and/or related required remediation as part of a PRP Group and reserves have been established to satisfy the Company's expected obligations. The Company historically has resolved these issues within established reserve levels and reasonably expects this result will continue. In addition to these non-owned sites, the Company has an ongoing practice of providing reserves for probable remediation activities at certain of its current or previously owned manufacturing locations (the "owned" sites). For claims and proceedings against the Company with respect to other environmental matters, reserves are established once the Company has determined that a loss is probable and estimable. This estimate is refined as the Company moves through the various stages of investigation, risk assessment, feasibility study and corrective action processes. In certain instances, the Company has developed a range of estimates for such costs and has recorded a liability based on the best estimate. It is reasonably possible that the actual cost of remediation of the individual sites could vary from the current estimates and the amounts accrued in the consolidated financial statements; however, the amounts of such variances are not expected to result in a material change to the consolidated financial statements. In estimating the Company's liability for remediation, the Company also considers the likely proportionate share of the anticipated remediation expense and the ability of the other PRPs to fulfill their obligations.

Total environmental reserves at March 31, 2026 and December 31, 2025 were $40.4 million and $37.4 million, respectively, for both non-owned and owned sites. For the three months ended March 31, 2026, the Company recorded $5.2 million in reserves. Additionally, the Company spent $2.2 million on environmental matters for the three months ended March 31, 2026.

The Company has agreements with other former owners of certain of its acquired businesses, as well as new owners of previously owned businesses. Under certain of the agreements, the former or new owners retained, or assumed and agreed to indemnify the Company against, certain environmental and other liabilities under certain circumstances. The Company and some of these other parties also carry insurance coverage for some environmental matters.

The Company believes it has established reserves for the environmental matters described above, which are sufficient to perform all known responsibilities under existing claims and consent orders. In the opinion of management, based on presently available information and the Company's historical experience related to such matters, an adequate provision for probable costs has been made and the ultimate cost resulting from these actions is not expected to materially affect the consolidated results of operations, financial position or cash flows of the Company.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

**15.&nbsp;&nbsp;&nbsp;&nbsp;Reportable Segments**

The Company has two reportable segments, Electronic Instruments Group and Electromechanical Group. The Company identifies its operating segments for segment reporting purposes primarily on the basis of product type, production processes, distribution methods and management organizations.

Reportable Segment Financial Information (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| | **EMG** | **EIG** | **Corporate** | **Total Consolidated** |
| Net Sales | $**663901** | $**1264536** | $**—** | $**1928437** |
| Cost of sales <sup>(1)</sup> | **470092** | **740786** | **—** | **1210878** |
| Selling expense | **23043** | **149812** | **—** | **172855** |
| Segment Operating Income | **170766** | **373938** | **—** | **544704** |
| Corporate G&A | **—** | **—** | **29768** | **29768** |
| Operating Income | **170766** | **373938** | **(29768)** | **514936** |
| Interest expense | **—** | **—** | **(20909)** | **(20909)** |
| Other (expense) income, net | **—** | **—** | **(1047)** | **(1047)** |
| Income before Income Taxes | $**170766** | $**373938** | $**(51724)** | $**492980** |
| Depreciation | **15446** | **19178** | **1637** | **36261** |
| Amortization | **18403** | **50826** | **—** | **69229** |
| Total depreciation and amortization | $**33849** | $**70004** | $**1637** | $**105490** |
| Research, Development & Engineering costs <sup>(2)</sup>  | $**22531** | $**89045** | $**—** | $**111576** |
| Assets | $**4871662** | $**10738867** | $**699006** | $**16309535** |
| Capital Expenditures | $**9344** | $**12841** | $**3283** | $**25468** |

---

(1)Includes $1.6 million of acquisition-related costs.

(2)Included in cost of sales.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**AMETEK, Inc.**

**Notes to Consolidated Financial Statements**

**March 31, 2026**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| | **EMG** | **EIG** | **Corporate** | **Total Consolidated** |
| Net Sales | $588298 | $1143673 | $— | $1731971 |
| Cost of sales | 437788 | 669183 |  | 1106971 |
| Selling expense | 21792 | 120440 |  | 142232 |
| Segment Operating Income | 128718 | 354050 |  | 482768 |
| Corporate G&A |  |  | 27939 | 27939 |
| Operating Income | 128718 | 354050 | (27939) | 454829 |
| Interest expense |  |  | (18993) | (18993) |
| Other (expense) income, net |  |  | (1614) | (1614) |
| Income before Income Taxes | $128718 | $354050 | $(48546) | $434222 |
| Depreciation | $15393 | $18757 | $1436 | $35586 |
| Amortization | 26643 | 44138 |  | 70781 |
| Total depreciation and amortization | $42036 | $62895 | $1436 | $106367 |
| Research, Development & Engineering costs <sup>(1)</sup>  | $21243 | $73622 | $— | $94865 |
| Assets | $4807148 | $9459042 | $610906 | $14877096 |
| Capital Expenditures | $7164 | $10403 | $5502 | $23069 |

---

(1)Included in cost of sales.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

**Recent Trends**

Recent geopolitical developments in the Middle East, including the conflict involving Iran, have contributed to increased uncertainty in global markets. Although we have limited Middle East sales exposure and do not have material operations or assets located in the region, we are not immune to the broader macroeconomic uncertainty an extended conflict may create on the global economy.

Our businesses have been proactive in addressing the impacts of tariffs, including targeted pricing initiatives, strategic adjustments to our global supply chains, and leveraging our worldwide manufacturing footprint to localize production and adapt to changing demand patterns. While recent tariff-related changes did not have a material impact on our results of operations for the three months ended March 31, 2026, as the situation continues to evolve, we cannot be certain of the outcome, which could adversely impact demand for our products, costs, inflation, customers, suppliers, and the overall global economy. We continue to monitor and analyze the impacts of the tariffs and the evolving macroeconomic environment and will continue to implement appropriate actions as necessary to mitigate their effects on our businesses.

**Results of Operations**

For the quarter ended March 31, 2026, the Company posted record operating income, orders, and backlog, as well as strong operating margins. Contributions from the acquisitions of FARO Technologies ("FARO") in July 2025 and LKC Technologies in January 2026 as well as our Operational Excellence initiatives had a positive impact on the first quarter of 2026 results. The Company recorded $1.6 million of pre-tax acquisition-related costs related to the FARO acquisition, which are comprised of ongoing integration costs, in the first quarter of 2026. These integration costs are recorded in Cost of sales and primarily include employee severance.

***Results of operations for the first quarter of 2026 compared with the first quarter of 2025***

Net sales for the first quarter of 2026 were $1,928.4 million, an increase of $196.4 million or 11.3%, compared with net sales of $1,732.0 million for the first quarter of 2025. The increase in net sales for the first quarter of 2026 was due to a 5% increase in organic sales, a 4% increase from acquisitions, as well as a 2% favorable effect of foreign currency translation.

Total international sales for the first quarter of 2026 were $923.7 million or 47.9% of net sales, an increase of $119.3 million or 14.8%, compared with international sales of $804.4 million or 46.4% of net sales for the first quarter of 2025. The increase in international sales was primarily driven by higher demand in Europe and Asia, as well as contributions from recent acquisitions.

Orders for the first quarter of 2026 were a record $2,217.6 million, an increase of $419.8 million or 23.3%, compared with $1,797.8 million for the first quarter of 2025. The increase in orders for the first quarter of 2026 was due to a 22% increase in organic orders, a 2% increase from acquisitions, partially offset by a 1% unfavorable effect of foreign currency translation. The Company's backlog of unfilled orders at March 31, 2026 was a record $3,870.7 million, an increase of $289.2 million or 8.1% compared with $3,581.5 million at December 31, 2025.

Cost of sales for the first quarter of 2026 was $1,210.9 million or 62.8% of net sales, an increase of $103.9 million or 9.4%, compared with $1,107.0 million or 63.9% of net sales for the first quarter of 2025. The cost of sales increase was primarily due to the net sales increase discussed above, partially offset by continued benefits from the Company's Operational Excellence initiatives.

Segment operating income for the first quarter of 2026 was $544.7 million, an increase of $61.9 million or 12.8%, compared with segment operating income of $482.8 million for the first quarter of 2025. Segment operating margins, as a percentage of net sales, increased to 28.2% for the first quarter of 2026, compared with 27.9% for the first quarter of 2025. In the first quarter of 2026, segment operating margins were negatively impacted 90 basis points by the dilutive impact of recent acquisitions and 10 basis points from acquisition-related costs. Excluding the dilutive impact of recent acquisitions and acquisition-related costs, segment operating margins increased 130 basis points compared to the first quarter of 2025 due to the sales increase discussed above, as well as continued benefits from the Company's Operational Excellence initiatives.

Selling, general and administrative expenses for the first quarter of 2026 were $202.6 million or 10.5% of net sales, an increase of $32.4 million or 19.1%, compared with $170.2 million or 9.8% of net sales for the first quarter of 2025. Selling expenses increased primarily due to the net sales increase discussed above, as well as higher selling expense related to recent

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

acquisitions. General and administrative expenses for the first quarter of 2026 were $29.8 million, compared with $27.9 million for the first quarter of 2025.

Consolidated operating income was a record $514.9 million or 26.7% of net sales for the first quarter of 2026, an increase of $60.1 million or 13.2%, compared with $454.8 million or 26.3% of net sales for the first quarter of 2025. In the first quarter of 2026, operating margins were negatively impacted 80 basis points by the dilutive impact of recent acquisitions and 10 basis points from acquisition-related costs. Excluding the dilutive impact of recent acquisitions and acquisition-related costs, operating margins increased 130 basis points compared to the first quarter of 2025 due to the sales increase discussed above, as well as continued benefits from the Company's Operational Excellence initiatives.

Interest expense for the first quarter of 2026 was $20.9 million, an increase of $1.9 million or 10.1%, compared with $19.0 million for the first quarter of 2025.

Other expense, net was $1.0 million for the first quarter of 2026, compared with $1.6 million of other expense, net for the first quarter of 2025.

The effective tax rate for the first quarter of 2026 and 2025 was 19.0%.

Net income for the first quarter of 2026 was $399.4 million, an increase of $47.6 million or 13.5%, compared with $351.8 million for the first quarter of 2025.

Diluted earnings per share for the first quarter of 2026 were a record $1.74, an increase of $0.22 or 14.5%, compared with $1.52 per diluted share for the first quarter of 2025.

***Segment Results***

**EIG*'***s net sales totaled $1,264.5 million for the first quarter of 2026, an increase of $120.8 million or 10.6%, compared with $1,143.7 million for the first quarter of 2025. The net sales increase was due to a 2% organic sales increase, 7% increase from recent acquisitions, as well as a 1% favorable effect of foreign currency translation.

EIG's operating income was $373.9 million for the first quarter of 2026, an increase of $19.8 million or 5.6%, compared with $354.1 million for the first quarter of 2025. EIG's operating margins were 29.6% of net sales for the first quarter of 2026, compared with 31.0% for the first quarter of 2025. In the first quarter of 2026, EIG's operating margins were negatively impacted 140 basis points by the dilutive impact of recent acquisitions and 10 basis points from acquisition-related expenses. Excluding the dilutive impact of recent acquisitions and acquisition-related expenses, EIG's operating margins increased 10 basis points compared to the first quarter of 2025 due to the sales increase discussed above, as well as continued benefits from the Company's Operational Excellence initiatives.

**EMG's** net sales totaled a record $663.9 million for the first quarter of 2026, an increase of $75.6 million or 12.9%, compared with $588.3 million for the first quarter of 2025. The net sales increase was due to a 11% organic sales increase, as well as a 2% favorable effect of foreign currency translation.

EMG's operating income was a record $170.8 million for the first quarter of 2026, an increase of $42.1 million or 32.7%, compared with $128.7 million for the first quarter of 2025. EMG's operating margins were 25.7% of net sales for the first quarter of 2026, compared with 21.9% for the first quarter of 2025. EMG's operating margins increased 380 basis points compared to the first quarter of 2025 due to the sales increase discussed above, as well as continued benefits from the Company's Operational Excellence initiatives.

**Financial Condition**

***Liquidity and Capital Resources***

Cash provided by operating activities totaled $451.5 million for the first three months of 2026, an increase of $34.0 million or 8.1%, compared with $417.5 million for the first three months of 2025. The increase in cash provided by operating activities for the first three months of 2026 was primarily due to higher net income, partially offset by higher working capital requirements.

Free cash flow (cash flow provided by operating activities less capital expenditures) was $426.0 million for the first three months of 2026, compared with $394.4 million for the first three months of 2025. EBITDA (earnings before interest,

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

income taxes, depreciation and amortization) was $618.3 million for the first three months of 2026, compared with $558.5 million for the first three months of 2025. Free cash flow and EBITDA are presented because the Company is aware that they are measures used by third parties in evaluating the Company.

Cash used by investing activities totaled $234.6 million for the first three months of 2026, compared with cash used by investing activities of $125.7 million for the first three months of 2025. For the first three months of 2026, the Company paid $209.6 million, net of cash acquired, to purchase LKC Technologies. For the first three months of 2025, the Company paid $103.2 million, net of cash acquired, to purchase Kern Microtechnik. Additions to property, plant and equipment totaled $25.5 million for the first three months of 2026, compared with $23.1 million for the first three months of 2025.

Cash used by financing activities totaled $188.0 million for the first three months of 2026, compared with cash used by financing activities of $277.7 million for the first three months of 2025. At March 31, 2026, total debt, net was $2,177.5 million, compared with $2,283.3 million at December 31, 2025. For the first three months of 2026, total borrowings decreased by $82.7 million compared with a $185.1 million decrease for the first three months of 2025. At March 31, 2026, the Company had available borrowing capacity of $1,573.4 million under its revolving credit facility, excluding the $700 million accordion feature.

The debt-to-capital ratio was 16.6% at March 31, 2026, compared with 17.7% at December 31, 2025. The net debt-to-capital ratio (total debt, net less cash and cash equivalents divided by the sum of net debt and stockholders' equity) was 13.4% at March 31, 2026, compared with 14.7% at December 31, 2025. The net debt-to-capital ratio is presented because the Company is aware that this measure is used by third parties in evaluating the Company.

Additional financing activities for the first three months of 2026 included cash dividends paid of $77.8 million, compared with $71.5 million for the first three months of 2025. Effective February 12, 2026, the Company's Board of Directors approved an 10% increase in the quarterly cash dividend on the Company's common stock to $0.34 per common share from $0.31 per common share. The Company repurchased $27.9 million of its common stock for the first three months of 2026, compared with $18.0 million for the first three months of 2025. Proceeds from stock option exercises were $9.6 million for the first three months of 2026, compared with $4.7 million for the first three months of 2025.

As a result of all of the Company's cash flow activities for the first three months of 2026, cash and cash equivalents at March 31, 2026 totaled $481.3 million, compared with $458.0 million at December 31, 2025. At March 31, 2026, the Company had $380.5 million in cash outside the United States, compared with $374.5 million at December 31, 2025. The Company utilizes this cash to fund its international operations, as well as to acquire international businesses. The Company is in compliance with all covenants, including financial covenants, for all of its debt agreements. The Company believes it has sufficient cash-generating capabilities from domestic and unrestricted foreign sources, available credit facilities and access to long-term capital funds to enable it to meet its operating needs and contractual obligations in the foreseeable future.

*Acquisition subsequent to March 31, 2026*

In April 2026, the Company entered into a definitive agreement to acquire First Aviation Services, Inc. ("First Aviation"), a leading provider of highly engineered, mission-critical defense and aviation maintenance, repair and overhaul services and a manufacturer of related proprietary components. First Aviation has annual sales of approximately $80 million. First Aviation will join the Electromechanical Group.

**Critical Accounting Policies**

The Company's critical accounting policies are detailed in Part II, Item 7, Management's Discussion and Analysis of Financial Condition of its Annual Report on Form 10-K for the year ended December 31, 2025. Primary disclosure of the Company's significant accounting policies is also included in Note 1 to the Consolidated Financial Statements included in Part II, Item 8 of its Annual Report on Form 10-K.

**Forward-Looking Information**

Information contained in this discussion, other than historical information, is considered "forward-looking statements" and is subject to various factors and uncertainties that may cause actual results to differ significantly from expectations. These factors and uncertainties include risks related to the Company's ability to consummate and successfully integrate future acquisitions; risks associated with international sales and operations, including supply chain disruptions; tariffs, trade disputes and currency conditions; the Company's ability to successfully develop new products, open new facilities or transfer product lines; the price and availability of raw materials; compliance with government regulations, including environmental regulations; changes in the competitive environment or the effects of competition in the Company's markets; the ability to maintain

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

adequate liquidity and financing sources; and general economic conditions affecting the industries the Company serves. A detailed discussion of these and other factors that may affect the Company's future results is contained in AMETEK's filings with the U.S. Securities and Exchange Commission, including its most recent reports on Form 10-K, 10-Q, and 8-K. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements, unless required by the securities laws to do so.

**Item 4. Controls and Procedures**

The Company maintains a system of disclosure controls and procedures that is designed to provide reasonable assurance that information, which is required to be disclosed, is accumulated and communicated to management in a timely manner. Under the supervision and with the participation of our management, including the Company's principal executive officer and principal financial officer, we have evaluated the effectiveness of our system of disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of March 31, 2026. Based on that evaluation, the Company's principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.

Such evaluation did not identify any change in the Company's internal control over financial reporting during the quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**PART II. OTHER INFORMATION**

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Purchase of equity securities by the issuer and affiliated purchasers.

The following table reflects purchases of AMETEK, Inc. common stock by the Company during the three months ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number<br>of Shares<br>Purchased (1)(2)** | **Average Price**<br>**Paid per Share** | **Total Number<br>of Shares<br>Purchased as<br>Part of Publicly<br>Announced<br>Plan (2)** | **Approximate**<br>**Dollar Value of**<br>**Shares that**<br>**May Yet Be**<br>**Purchased Under**<br>**the Plan** |
| January 1, 2026 to January 31, 2026 |  | $— |  | $806994962 |
| February 1, 2026 to February 28, 2026 |  |  |  | 806994962 |
| March 1, 2026 to March 31, 2026 | 37323 | 212.58 | 37323 | 799060816 |
| Total | 37323 | $212.58 | 37323 |  |

---

________________

(1)&nbsp;&nbsp;&nbsp;&nbsp;Represents shares surrendered to the Company to satisfy tax withholding obligations in connection with employees' share-based compensation awards.

(2) &nbsp;&nbsp;&nbsp;&nbsp;Effective February 7, 2025, the Company's Board of Directors approved a $1.25 billion share repurchase

authorization. This new authorization replaces the previous $1 billion share repurchase authorization approved in

May 2022. Consists of the number of shares purchased pursuant to the Company's Board of Directors $1.25 billion authorization for the repurchase of its common stock. Such purchases may be effected from time to time in the open market or in private transactions, subject to market conditions and at management's discretion.

**Item 5. Other Information**

**Insider Trading Arrangements and Policies**

During the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| <u>[31.1\*](ame-20260331xexx311.htm)</u> | <u>[Certification of Chief Executive Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ame-20260331xexx311.htm)</u> |
| <u>[31.2\*](ame-20260331xexx312.htm)</u> | <u>[Certification of Chief Financial Officer, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ame-20260331xexx312.htm)</u> |
| <u>[32.1\*](ame-20260331xexx321.htm)</u> | <u>[Certification of Chief Executive Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ame-20260331xexx321.htm)</u> |
| <u>[32.2\*](ame-20260332xexx322.htm)</u> | <u>[Certification of Chief Financial Officer, Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ame-20260332xexx322.htm)</u> |
| 101.INS\* | XBRL Instance Document. |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\* | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101). |

---

________________

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed electronically herewith.

------

<u>[**Table of Contents**](#ib9dd6fad079d4766b2733344dd3cbc40_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | By: | <u>AMETEK, Inc.</u><br>/s/ ROBERT J. AMODEI |
| | | Robert J. Amodei |
| | | Senior Vice President – Controller |
| | | (Principal Accounting Officer) |
| April 30, 2026 |  |  |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, David A. Zapico, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AMETEK, Inc. (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 30, 2026

---

| |
|:---|
| /s/ DAVID A. ZAPICO |
| David A. Zapico |
| Chairman of the Board and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Dalip M. Puri, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 30, 2026

---

| |
|:---|
| /s/ DALIP M. PURI |
| Dalip M. Puri |
| Executive Vice President – Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**AMETEK, Inc.**

**Certification Pursuant to**

**18 U.S.C. Section 1350, as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of AMETEK, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, David A. Zapico, Chairman of the Board and Chief Executive Officer of the Company, certify to such officer's knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ DAVID A. ZAPICO |
| David A. Zapico |
| Chairman of the Board and Chief Executive Officer |

---

Date: April 30, 2026

## Exhibit 32.2

**Exhibit 32.2**

**AMETEK, Inc.**

**Certification Pursuant to**

**18 U.S.C. Section 1350, as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of AMETEK, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dalip M. Puri, Executive Vice President – Chief Financial Officer of the Company, certify to such officer's knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ DALIP M. PURI |
| Dalip M. Puri |
| Executive Vice President – Chief Financial Officer |

---

Date: April 30, 2026

<br>